This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (311) Diabetes (187) Pilot studies (non-ehealth) (65) Chronic Conditions (270)

Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/56067, first published .
Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project)

Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project)

Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project)

Authors of this article:

Steffen Flindt Nielsen1, 2 Author Orcid Image ;   Camilla Lundgreen Duus1, 2 Author Orcid Image ;   Niels Henrik Buus2, 3 Author Orcid Image ;   Jesper Nørgaard Bech1, 2 Author Orcid Image ;   Frank Holden Mose1, 2 Author Orcid Image
Article Authors Cited by (2) Tweetations (3) Metrics

Journals

  1. Nielsen S, Duus C, Buus N, Bech J, Mose F. Randomized, Placebo-Controlled Trial on the Renal and Systemic Hemodynamic Effects of Empagliflozin. Kidney International Reports 2024 View
  2. Jensen M, Nielsen S, Thiel S, Hansen S, Palarasah Y, Svenningsen P, Bech J, Mose F, Jensen B. Pilot study of SGLT-2 inhibitor empagliflozin shows reduced intrarenal complement activation in patients with diabetes and chronic kidney disease. Kidney International Reports 2024 View